|
Breast Carcinoma
|
0.600 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Breast Carcinoma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overexpression of HER2/p185HER2 is strongly correlated with progression of human ovarian and breast carcinomas.
|
1346155 |
1992 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The results of this study suggest that c-erbB-2 protein overexpression, a marker of poor prognosis in breast cancer, is associated with a lack of response to endocrine therapy on relapse, and particularly in combination with EGFR may be useful in directing therapeutic choices.
|
1346366 |
1992 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Differences in breast cancer risk factors to neu (c-erbB-2) protein overexpression of the breast tumor.
|
1348449 |
1992 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This study suggests that overexpression of the c-erbB-2 oncoprotein appears to be an important indicator of relapse in stage I-II breast cancer when singly evaluated.
|
1349034 |
1992 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This high incidence of HER2 gene amplification with accompanying overexpression in non-invasive breast tumors suggests that perturbations of the HER2 oncogene are among the earliest and most common genetic lesions in human breast cancer.
|
1349163 |
1992 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, the oncogene ERBB-2 is often amplified in human tumors, but breast cancer is characterized by an especially high frequency of ERBB-2 amplification.
|
1349430 |
1992 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.
|
1351537 |
1992 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.
|
1351538 |
1992 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The relative ERBB2 copy number determined by FISH in 10 breast cancer cell lines correlated strongly with Southern blot results (r = 0.98) when probes for an identical reference locus were used in the two methods.
|
1351679 |
1992 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Alterations of the c-erbB2 gene in human breast cancer.
|
1352298 |
1992 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overexpression of the p53 and c-erbB-2 proteins indicates a high malignant potential in ANN breast cancer, but it is not a significant prognostic factor independent of the cell proliferation rate.
|
1352359 |
1992 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Amplification of HER-2/neu, a protooncogene related to the epidermal growth factor receptor, has prognostic significance in patients with breast cancer.
|
1353638 |
1992 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Amplification of the c-erbB-2 protooncogene and DNA aneuploidy have been reported to correlate with poor patient prognosis in human breast cancer.
|
1353701 |
1992 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Over-expression of the proto-oncogene HER-2 (c-erbB-2/neu) in ovarian, endometrial, and mammary carcinoma is an indicator of poor prognosis.
|
1355758 |
1992 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Different assays for HER-2/neu evaluation in breast cancer.
|
1355935 |
1992 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells.
|
1356014 |
1992 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The BSMZ cell line may therefore provide a useful model for the study of human breast cancer and overexpression of the erbB-2 gene.
|
1356615 |
1992 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ninety-seven unselected breast carcinomas were immunostained for estrogen and progesterone receptors, Ki-67 proliferation-associated antigen, p53 tumor suppressor gene product (p53), and c-erbB-2 protein.
|
1357956 |
1992 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Amplification and overexpression of the c-erbB-2 oncogene have been associated with a poor prognosis in breast cancer.
|
1358045 |
1992 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This provides us with an explanation for the discrepancies in literature concerning c-erbB-2 expression and prognosis in breast cancer.
|
1358163 |
1992 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, the level of c-erbB-2-protein was investigated by immunohistochemistry in 271 breast carcinomas which were operated in the years 1984-1987.
|
1361480 |
1992 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer.
|
1362164 |
1992 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques.
|
1363511 |
1993 |